文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

未治疗人群中结核菌素皮肤试验或干扰素-γ释放试验阳性者的结核病绝对风险:系统评价和荟萃分析。

Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis.

机构信息

Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.

McGill International TB Centre, Montreal, QC, Canada.

出版信息

BMJ. 2020 Mar 10;368:m549. doi: 10.1136/bmj.m549.


DOI:10.1136/bmj.m549
PMID:32156698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7190060/
Abstract

OBJECTIVE: To determine the annual rate of tuberculosis development after a positive tuberculin skin test (TST) or interferon-gamma release assay result (IGRA), or both, among untreated populations with characteristics believed to increase the risk of tuberculosis (at risk populations). DESIGN: Systematic review and meta-analysis. DATA SOURCES: Embase, Medline, and Cochrane Controlled Register of Trials from 1 January 1990 to 17 May 2019, for studies in humans published in English or French. Reference lists were reviewed. ELIGIBILITY CRITERIA AND DATA ANALYSIS: Retrospective or prospective cohorts and randomised trials that included at least 10 untreated participants who tested positive to tuberculosis antigens (contained in TST or IGRA, or both) followed for at least 12 months. Following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and meta-analyses of observational studies in epidemiology (MOOSE) guidelines, two reviewers independently extracted study data and assessed quality using a modified quality assessment of diagnostic accuracy studies (QUADAS-2) tool. Data were pooled using random effects generalised linear mixed models. MAIN OUTCOME MEASURES: The primary outcome was tuberculosis incidence per 1000 person years among untreated participants who tested positive (TST or IGRA, or both) in different at risk subgroups. Secondary outcomes were the cumulative incidence of tuberculosis and incidence rate ratios among participants with a positive test result for latent tuberculosis infection compared with those with a negative test result in at risk subgroups. RESULTS: 122 of 5166 identified studies were included. In three general population studies, the incidence of tuberculosis among 33 811 participants with a TST induration of ≥10 mm was 0.3 (95% confidence interval 0.1 to 1.1) per 1000 person years. Among 116 197 positive test results for latent tuberculosis infection in 19 different at risk populations, incidence rates were consistently higher than those in the general population. Among all types of tuberculosis contacts, the incidence of tuberculosis was 17.0 (95% confidence interval 12.9 to 22.4) per 1000 person years for participants with a positive IGRA result and 8.4 (5.6 to 12.6) per 1000 person years for participants with a positive TST result of ≥5 mm. Among people living with HIV, the incidence of tuberculosis was 16.9 (10.5 to 27.3) for participants with a positive IGRA result and 27.1 (15.0 to 49.0) for participants with a positive TST result of ≥5 mm. Rates were also high for immigrants, people with silicosis or requiring dialysis, transplant recipients, and prisoners. Incidence rate ratios among test positive versus test negative participants were significantly greater than 1.0 in almost all risk groups, for all tests. CONCLUSIONS: The incidence of tuberculosis is substantial in numerous at risk populations after a positive TST or IGRA result. The information from this review should help inform clinical decisions to test and treat for latent tuberculosis infection. STUDY REGISTRATION: PROSPERO CRD42019136608.

摘要

目的:确定在未治疗的高危人群中,结核菌素皮肤试验(TST)或干扰素-γ释放试验(IGRA)阳性或两者均阳性的人群中,未经治疗的人群中结核病的年发病率。

设计:系统评价和荟萃分析。

数据来源:1990 年 1 月 1 日至 2019 年 5 月 17 日,Embase、Medline 和 Cochrane 对照试验注册中心,检索英文或法文发表的人类研究。审查了参考文献列表。

入选标准和数据分析:回顾性或前瞻性队列研究和随机试验,包括至少 10 名未接受治疗的参与者,他们对结核抗原(包含在 TST 或 IGRA 中,或两者均阳性)进行了检测,随访至少 12 个月。根据系统评价和荟萃分析的首选报告项目(PRISMA)和流行病学中观察性研究的荟萃分析(MOOSE)指南,两名审查员独立提取研究数据,并使用改良的诊断准确性研究质量评估工具(QUADAS-2)评估质量。使用随机效应广义线性混合模型进行数据汇总。

主要结局指标:未经治疗的参与者中,TST 或 IGRA 阳性的结核病发病率(每 1000 人年中的发病例数)为主要结局指标。不同高危亚组中,潜伏性结核感染阳性试验结果与阴性试验结果相比,参与者的累积结核病发病率和发病率比为次要结局指标。

结果:在 5166 项确定的研究中,有 122 项被纳入。在三项一般人群研究中,33811 名 TST 硬结度≥10mm 的参与者中,结核病的发病率为 0.3(95%置信区间 0.1 至 1.1)/1000 人年。在 19 个不同高危人群中,116197 例潜伏性结核感染阳性检测结果中,发病率始终高于一般人群。在所有类型的结核接触者中,IGRA 阳性结果的参与者中结核病的发病率为 17.0(95%置信区间 12.9 至 22.4)/1000 人年,TST 阳性结果≥5mm 的参与者中结核病的发病率为 8.4(5.6 至 12.6)/1000 人年。在艾滋病毒感染者中,IGRA 阳性结果的参与者中结核病的发病率为 16.9(10.5 至 27.3),TST 阳性结果≥5mm 的参与者中结核病的发病率为 27.1(15.0 至 49.0)。移民、矽肺或需要透析、移植受者和囚犯的发病率也很高。在几乎所有的风险群体中,与试验阴性参与者相比,试验阳性参与者的发病率比都显著大于 1.0,所有的试验结果均如此。

结论:在许多高危人群中,TST 或 IGRA 阳性后结核病的发病率很高。本综述的信息应有助于为潜伏性结核感染的检测和治疗提供决策依据。

研究注册:PROSPERO CRD42019136608。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52f2/7190060/f1a55d64e710/camj052371.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52f2/7190060/f1a55d64e710/camj052371.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52f2/7190060/f1a55d64e710/camj052371.f1.jpg

相似文献

[1]
Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis.

BMJ. 2020-3-10

[2]
The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis.

Lancet Infect Dis. 2022-2

[3]
Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study.

Health Technol Assess. 2018-10

[4]
Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis.

BMC Infect Dis. 2017-3-9

[5]
A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants.

Mol Diagn Ther. 2015-2

[6]
Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis.

Lancet Infect Dis. 2020-12

[7]
Interferon-γ release assay as a sensitive diagnostic tool of latent tuberculosis infection in patients with HIV: a cross-sectional study.

BMC Infect Dis. 2018-11-19

[8]
Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.

BMC Infect Dis. 2015-2-14

[9]
Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays.

BMC Public Health. 2016-8-25

[10]
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study.

Lancet Infect Dis. 2022-1

引用本文的文献

[1]
Rapid molecular testing or chest X-ray or tuberculin skin testing for household contact assessment of tuberculosis infection: A cluster-randomized trial.

PLoS Med. 2025-7-28

[2]
An Update on the Clinical Management of HIV and Tuberculosis Co-Infection in Pregnancy: TB Preventative Therapy, Long-Acting ARVs, and Bedaquiline-Based Regimens.

Curr HIV/AIDS Rep. 2025-6-16

[3]
Modeling the impact of case finding for tuberculosis: The role of infection dynamics.

medRxiv. 2025-4-16

[4]
Brazilian recommendations for the management of tuberculosis infection in immune-mediated inflammatory diseases.

Adv Rheumatol. 2025-3-20

[5]
TB antigen-based skin tests and QFT-Plus for Mycobacterium tuberculosis infection diagnosis in Brazilian healthcare workers: a cost-effectiveness analysis.

Cad Saude Publica. 2025-2-24

[6]
Latent Tuberculosis Screening and Active Tuberculosis Disease Development in People Living with HIV: A Multicenter Retrospective Cohort Study in Turkiye.

Curr HIV Res. 2025

[7]
Interferon-Gamma Release Assay Testing for Latent Tuberculosis Infection: A Health Technology Assessment.

Ont Health Technol Assess Ser. 2024-12-12

[8]
Advances in the Diagnosis of Latent Tuberculosis Infection.

Infect Drug Resist. 2025-1-25

[9]
Diagnosis and Treatment of Latent Tuberculosis Infection in Adults in South Korea.

Tuberc Respir Dis (Seoul). 2025-1

[10]
Rethinking latent TB? Think again.

IJTLD Open. 2024-8-1

本文引用的文献

[1]
Assessing the Impact of Isoniazid Preventive Therapy (IPT) on Tuberculosis Incidence and Predictors of Tuberculosis among Adult Patients Enrolled on ART in Nekemte Town, Western Ethiopia: A Retrospective Cohort Study.

Interdiscip Perspect Infect Dis. 2019-5-2

[2]
Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries.

PLoS Med. 2019-6-6

[3]
Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis.

Am J Kidney Dis. 2018-9-28

[4]
Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations.

BMC Med Res Methodol. 2018-5-21

[5]
Latent tuberculosis infection: An overview.

Can Commun Dis Rep. 2017-3-2

[6]
Physicians' perspectives on communication and decision making in clinical encounters for treatment of latent tuberculosis infection.

ERJ Open Res. 2018-3-23

[7]
Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis.

BMC Infect Dis. 2017-3-9

[8]
Diagnosis and Management of Latent Tuberculosis Infection.

Cold Spring Harb Perspect Med. 2015-6-8

[9]
Latent Mycobacterium tuberculosis infection.

N Engl J Med. 2015-5-28

[10]
Meta-analysis of incidence rate data in the presence of zero events.

BMC Med Res Methodol. 2015-4-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索